Potential Antimigraine Effects of Warfarin: An Exploration of Biological Mechanism with Survey of Patients

Benjamin Nilsson; Valentina Back; Ran Wei; Frances Plane; Paul Jurasz; Tammy J. Bungard

doi:10.1055/s-0039-1692989

TH Open, Table of Contents

CC BY 4.0 · TH Open 2019; 03(02): e180-e189
DOI: 10.1055/s-0039-1692989

Original Article

Georg Thieme Verlag KG Stuttgart · New York

Potential Antimigraine Effects of Warfarin: An Exploration of Biological Mechanism with Survey of Patients

Authors

Benjamin Nilsson

¹Alberta Health Services, Edmonton, Alberta, Canada

²Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada
Valentina Back

²Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada

³Cardiovascular Research Centre, University of Alberta, Edmonton, Alberta, Canada
Ran Wei

³Cardiovascular Research Centre, University of Alberta, Edmonton, Alberta, Canada

⁴Department of Pharmacology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada
Frances Plane

³Cardiovascular Research Centre, University of Alberta, Edmonton, Alberta, Canada

⁴Department of Pharmacology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada
Paul Jurasz^*

²Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada

³Cardiovascular Research Centre, University of Alberta, Edmonton, Alberta, Canada

⁴Department of Pharmacology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada

⁵Alberta Mazankowski Heart Institute, University of Alberta, Edmonton, Alberta, Canada
Tammy J. Bungard^*

⁶Department of Cardiology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada

Abstract

Case reports suggest a link between anticoagulant use and improved migraine symptoms, and a role for platelet-induced cerebral vasoconstriction in migraine pathobiology. Hence, we investigated the mechanism by which warfarin may affect migraine symptoms and whether there is a change in migraine symptomology in patients initiating oral anticoagulants, most commonly warfarin. The effects of warfarin on human platelet aggregation and secretion as well as platelet-induced rat cerebral artery vasoconstriction were studied. A survey of migraine and symptom change after starting or stopping oral anticoagulants was also conducted. Warfarin inhibited platelet aggregation and 5-hydroxytryptamine (5-HT) secretion in a concentration-dependent manner. Warfarin-inhibited platelet secretion products constricted middle cerebral arteries from male but not from female rats. For the survey, patient demographic information, migraine and medical history, and Migraine Disability Assessment Score (MIDAS) changes were collected. Out of 175 consenting, 40 respondents met the criteria for migraine and completed the survey. A total of 11 patients reported migraine symptom change, all coinciding with starting warfarin. Of those having symptom and MIDAS improvement, most were female with migraines with aura, whereas those worsening were male with fewer having migraine with aura. Of those reporting migraine symptom change with warfarin, female sex may be associated with improved MIDAS, and those experiencing an aura component are more likely to report a symptom change. Warfarin-mediated symptom improvement in females may occur due to inhibition of platelet 5-HT secretion and a lower sensitivity of female cerebral blood vessels to platelet-derived 5-HT-induced vasoconstriction.

Keywords

warfarin - migraine - platelets - serotonin - blood vessels

Full Text

References

References
1 Wolff HG. Headache and Other Pain. 2nd ed. New York, NY: Oxford University Press; 1963
2 Andersen AR, Friberg L, Olsen TS, Olesen J. Delayed hyperemia following hypoperfusion in classic migraine. Single photon emission computed tomographic demonstration. Arch Neurol 1988; 45 (02) 154-159
3 Olesen J, Friberg L, Olsen TS. , et al. Timing and topography of cerebral blood flow, aura, and headache during migraine attacks. Ann Neurol 1990; 28 (06) 791-798
4 Ferrari MD. Migraine. Lancet 1998; 351 (9108): 1043-1051
5 Danese E, Montagnana M, Lippi G. Platelets and migraine. Thromb Res 2014; 134 (01) 17-22
6 Buttinelli C, Lazzaro MP, Lenzi GL, Paolucci S, Prencipe M. Correlation between migraine and circulating platelet aggregates. Cephalalgia 1985; 5 (02) (Suppl. 02) 87-88
7 Lechner H, Ott E, Fazekas F, Pilger E. Evidence of enhanced platelet aggregation and platelet sensitivity in migraine patients. Cephalalgia 1985; 5 (02) (Suppl. 02) 89-91
8 Tietjen GE, Al-Qasmi MM, Athanas K, Utley C, Herial NA. Altered hemostasis in migraineurs studied with a dynamic flow system. Thromb Res 2007; 119 (02) 217-222
9 Mück-Seler D, Deanović Z, Dupelj M. Platelet serotonin (5-HT) and 5-HT releasing factor in plasma of migrainous patients. Headache 1979; 19 (01) 14-17
10 Benemei S, Cortese F, Labastida-Ramírez A. , et al; School of Advanced Studies of the European Headache Federation (EHF-SAS). Triptans and CGRP blockade: impact on the cranial vasculature. J Headache Pain 2017; 18 (01) 103
11 Savi LT, Condello V, Bert F, Pinessi L. Prophylaxis of migraine with aura: a place for acetylsalicylic acid. J Headache Pain 2013; 14 (Suppl. 01) P195
12 Wilmshurst PT, Nightingale S, Walsh KP, Morrison WL. Clopidogrel reduces migraine with aura after transcatheter closure of persistent foramen ovale and atrial septal defects. Heart 2005; 91 (09) 1173-1175
13 Suresh CG, Neal D, Coupe MO. Warfarin treatment and migraine. Postgrad Med J 1994; 70 (819) 37-38
14 van Puijenbroek EP, Egberts AC, Trooster JF, Zomerdijk J. Reduction of migrainous headaches during the use of acenocoumarol. Headache 1996; 36 (01) 48-48
15 Fragoso YD. Reduction of migraine attacks during the use of warfarin. Headache 1997; 37 (10) 667-668
16 Souza JA, Moreira Filho PF, Jevoux Cda C, Martins GF, Pitombo AB. Remission of refractory chronic cluster headache after warfarin administrations: case report. Arq Neuropsiquiatr 2004; 62 (04) 1090-1091
17 Russo A, Santi S, Gueraldi D, De Paola M, Zani F, Pini LA. An unusual case report on the possible role of Warfarin in migraine prophylaxis. Springerplus 2013; 2 (01) 48
18 Nilsson BG, Bungard TJ. A case of migraine with aura resolving on warfarin but not on apixaban. Headache 2017; 57 (10) 1614-1617
19 Teng CM, Li HL, Wu TS, Huang SC, Huang TF. Antiplatelet actions of some coumarin compounds isolated from plant sources. Thromb Res 1992; 66 (05) 549-557
20 Leoncini G, Signorello MG, Bruzzese D, Di Braccio M, Grossi GC, Roma G. Mechanisms involved in the antiplatelet activity of 8-methyl-4-(1-piperazinyl)-7-(3-pyridinylmethoxy)-2H-1-benzopyran-2-one (RC414). Biochem Pharmacol 2004; 67 (05) 911-918
21 Macáková K, Řeháková Z, Mladěnka P. , et al. In vitro platelet antiaggregatory properties of 4-methylcoumarins. Biochimie 2012; 94 (12) 2681-2686
22 Schürks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T. Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ 2009; 339: b3914
23 Spector JT, Kahn SR, Jones MR, Jayakumar M, Dalal D, Nazarian S. Migraine headache and ischemic stroke risk: an updated meta-analysis. Am J Med 2010; 123 (07) 612-624
24 Moncada de la Rosa C, Radziwon-Balicka A, El-Sikhry H. , et al. Pharmacologic protein kinase Cα inhibition uncouples human platelet-stimulated angiogenesis from collagen-induced aggregation. J Pharmacol Exp Ther 2013; 345 (01) 15-24
25 Stewart WF, Lipton RB, Whyte J. , et al. An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. Neurology 1999; 53 (05) 988-994
26 Wammes-van der Heijden EA, Tijssen CC, van't Hoff AR, Egberts AC. A thromboembolic predisposition and the effect of anticoagulants on migraine. Headache 2004; 44 (05) 399-402
27 Di Braccio M, Grossi G, Roma G, Grazia Signorello M, Leoncini G. Synthesis and in vitro inhibitory activity on human platelet aggregation of novel properly substituted 4-(1-piperazinyl)coumarins. Eur J Med Chem 2004; 39 (05) 397-409
28 Ishimoto Y, Nakano T. Release of a product of growth arrest-specific gene 6 from rat platelets. FEBS Lett 2000; 466 (01) 197-199
29 Angelillo-Scherrer A, de Frutos P, Aparicio C. , et al. Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nat Med 2001; 7 (02) 215-221
30 Chan E, McLachlan AJ, Pegg M, MacKay AD, Cole RB, Rowland M. Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin. Br J Clin Pharmacol 1994; 37 (06) 563-569
31 Tiseo PJ, Foley K, Friedhoff LT. The effect of multiple doses of donepezil HCl on the pharmacokinetic and pharmacodynamic profile of warfarin. Br J Clin Pharmacol 1998; 46 (01) (Suppl. 01) 45-50
32 Shaik AN, Grater R, Lulla M. , et al. Comparison of enzyme kinetics of warfarin analyzed by LC-MS/MS QTrap and differential mobility spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2016; 1008: 164-173
33 Chen YL, Wang TC, Liang SC, Teng CM, Tzeng CC. Synthesis and evaluation of coumarin alpha-methylene-gamma-butyrolactones: a new class of platelet aggregation inhibitors. Chem Pharm Bull (Tokyo) 1996; 44 (08) 1591-1595
34 Kovacs IB, Murphy M, Barin E, Rees GM. Effect of warfarin on arterial thrombogenesis: problems of monitoring. Am J Hematol 1993; 42 (03) 322-327
35 Newland H, Nordöy A. Effect of large doses of warfarin sodium on haemostasis and on ADP-induced platelet aggregation in vivo in the rat. A survey of experimental thrombosis and coumarin anticoagulant therapy. Cardiovasc Res 1967; 1 (04) 362-370
36 Woronowicz K, Dilks JR, Rozenvayn N. , et al. The platelet actin cytoskeleton associates with SNAREs and participates in alpha-granule secretion. Biochemistry 2010; 49 (21) 4533-4542
37 Nilsson T, Longmore J, Shaw D, Olesen IJ, Edvinsson L. Contractile 5-HT1B receptors in human cerebral arteries: pharmacological characterization and localization with immunocytochemistry. Br J Pharmacol 1999; 128 (06) 1133-1140
38 Ku DD, Zaleski JK, Liu S, Brock TA. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am J Physiol 1993; 265 (2, Pt 2): H586-H592
39 Ahnstedt H, Cao L, Krause DN. , et al. Male-female differences in upregulation of vasoconstrictor responses in human cerebral arteries. PLoS One 2013; 8 (04) e62698
40 Hansen JM, Schankin CJ. Cerebral hemodynamics in the different phases of migraine and cluster headache. J Cerebral Blood Flow Metabol 2019; 39 (04) 595-609
41 Morales-Asín F, Iñiguez C, Cornudella R, Mauri JA, Espada F, Mostacero EE. Patients with acenocoumarol treatment and migraine. Headache 2000; 40 (01) 45-47
42 Maggioni F, Bruno M, Mainardi F, Lisotto C, Zanchin G. Migraine responsive to warfarin: an update on anticoagulant possible role in migraine prophylaxis. Neurol Sci 2012; 33 (06) 1447-1449
43 Cuadrado MJ, Khamashta MA, Hughes GRV. Migraine and stroke in young women. QJM 2000; 93 (05) 317-318
44 White RE. Estrogen and vascular function. Vascul Pharmacol 2002; 38 (02) 73-80
45 Iorga A, Cunningham CM, Moazeni S, Ruffenach G, Umar S, Eghbali M. The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy. Biol Sex Differ 2017; 8 (01) 33
46 Viguier F, Michot B, Hamon M, Bourgoin S. Multiple roles of serotonin in pain control mechanisms--implications of 5-HT₇ and other 5-HT receptor types. Eur J Pharmacol 2013; 716 (1-3): 8-16
47 Segelcke D, Messlinger K. Putative role of 5-HT_2B receptors in migraine pathophysiology. Cephalalgia 2017; 37 (04) 365-371
48 Peng KP, Chen YT, Fuh JL, Tang CH, Wang SJ. Migraine and incidence of ischemic stroke: a nationwide population-based study. Cephalalgia 2017; 37 (04) 327-335
49 Peng KP, Chen YT, Fuh JL, Tang CH, Wang SJ. Association between migraine and risk of venous thromboembolism: a nationwide cohort study. Headache 2016; 56 (08) 1290-1299